OXFORD
BIOMEDICA’S INNUREX® PRODUCT RESTORES LIMB FUNCTION
IN A PRECLINICAL MODEL OF AVULSION INJURY
Data
presented at the 7th Annual Meeting of the American Society
For Gene Therapy
Oxford
BioMedica (LSE: OXB), the leading gene therapy company,
announced today that preclinical
data from the Innurex nerve repair programme are being presented
by Dr. Nicholas Mazarakis, the Company’s Vice President
for Neurobiology, at the 7th Annual Meeting of the American
Society of Gene Therapy held in Minneapolis from June 2-6.
The data, which will shortly be sent for peer-reviewed publication,
show that Innurex is able to restore function to damaged
limbs in a model of avulsion (stretch) injury. These results
indicate that Innurex may have clinical benefit in patients
with nerve damage resulting from severe pull/stretch injury,
a common consequence of sporting and motor accidents.
Within the field of neurobiology nerve repair has been a
long sought goal for the treatment of nerve damage and spinal
injury. The aim is to induce nerve cells to regrow and bridge
sites of injury thereby reconnecting the nerve fibres and
restoring function. At present there are no effective therapies
for nerve damage and spinal injury.
The new results
with Innurex are the first functional data to come from
Oxford BioMedica’s nerve repair programme
and they indicate that the new nerve connections induced
by Innurex restore substantial function to limbs that have
a damaged nerve supply. The data were generated from an ongoing
collaboration between Oxford BioMedica and Professors Malcolm
Maden and Stephen McMahon at King’s College London.
Prof. Alan Kingsman,
Oxford BioMedica’s Chief Executive,
said: “Innurex goes from strength to strength. In
December of last year we announced that Innurex had been
shown to
induce nerve regrowth in vivo. We now know that the regrowth
is significant in that injured limbs regain both movement
and sensation as a result of treatment with Innurex.”
-
ends -
|
